Table 3.

Frequency of ICOS+ CD4 T cells in pre- and posttherapy samples after treatment with anti-CTLA-4

Patients with localized bladder cancer (ipilimumab therapy)Patients with metastatic melanoma (ipilimumab therapy)Patients with metastatic melanoma (gp100 DNA vaccine)
MeanSDPMeanSDPMeanSDP
Pretreatment2.361.18Ref.2.081.67Ref.2.701.25Ref.
Posttreatment (dose 1)13.334.140.0036.135.270.0012.700.950.92
Posttreatment (dose 2)16.2710.290.0047.466.180.0001